INTRODUCTION AND OBJECTIVES: Pannexin 1 (Panx1) channels play essential roles in urothelial mechanotransduction and signaling by providing a mechanosensitive conduit for ATP release in response to bladder distension. It has been proposed that urothelial ATP signaling to bladder sensory fibers relays the degree of bladder fullness and modulates detrusor activity, which are essential for proper micturition. Panx1 channels have been implicated in neurogenic bladder and bladder overactivity. However, little is known about the mechanisms that regulate Panx1 in the bladder. Our goal was to investigate the extent to which mechanical stimulation and bladder overdistension, as occurs with polyuria in diabetes, regulates Panx1 expression and function.
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METHODS: Studies were performed with a) mouse urothelial cell cultures and b) 10 week old C57BL/6 mice treated for 2 and 4 weeks with 5% sucrose in the drinking water (diuresis mouse model), and non-treated age-match control mice. Urothelial cells cultured on custom made stretchable silicone culture chambers were submitted to uniaxial stretch for 0, 2 and 5 hours (30 sec cycle duration; maximum strain~10%) and then immediately harvested and processed for quantification of Panx1 mRNA by real-time quantitative PCR (qPCR). Voided urine samples from sucrose-fed and control mice were collected for quantification of ATP levels using the luciferin-luciferase assay. Bladders were then isolated, the urothelium dissected and processed for qPCR analysis of Panx1 mRNA levels.
RESULTS: Prolonged cyclic mechanical stimulation (5hrs) resulted in significant reduction of Panx1 expression in urothelial cells when compared to non-stimulated cells or to shorter (2hrs) stimulation (5 hrs: 0.66 AE 0.07*; 2 hrs: 1.02 AE 0.05; 0 hrs: 1.01 AE 0.05; mRNA norm. to mean 0 hrs levels; N ¼ 6, *P<0.01). Panx1 expression in the bladder urothelium of mice after 2 and 4 weeks of sucrose-induced diuresis was significantly lower than in control mice (2 wks: 0.88 AE 0.05*; 4 wks: 0.74 AE 0.07*; Ctrl: 1.00 AE 0.03; mRNA norm. to mean Ctrl value; N ¼ 4, *P<0.01). Urine ATP levels (nM) in 2 and 4 weeks diuresis mice were also significantly lower when compared to those in control mice (2 wks: 7.1 AE 0.6*; 4 wks: 6.3 AE 0.5*; Ctrl: 38.7 AE 1.8; N ¼ 4, *P<0.0001), consistent with observed Panx1 downregulation.
CONCLUSIONS: Prolonged mechanical loading and overdistension reduce urothelial Panx1 expression and ATP release. This impairs proper urothelial ATP signaling and bladder mechanosensory activation, and may thereby contribute to development of detrusor underactivity. RhoA, Rac) are critical mediators of smooth muscle contraction in the lower urinary tract, which is involved in pathophysiology and therapy of lower urinary tract symptoms (LUTS). Rac has been recently identified as a novel intracellular mediator of prostate smooth muscle contraction. A similar role in the bladder appears now possible. Here, we addressed Rac function in the human trigone.
Source of
METHODS: Bladder tissues (trigone, dome, wall, mucosa) were obtained from patients undergoing radical cystectomy. Rac isoforms were detected by RT-PCR, Western blot, and immunofluorescence staining. Active Rac1 was detected by pull down assays using a GST/ PBD-PAK (glutathione S-transferase/p21 binding domain of p21-activated kinase) fusion protein, immobilized to glutathione-covered agarose beads. Contractility of trigone tissues was examined in an organ bath.
RESULTS: By RT-PCR, mRNA for Rac1, Rac2 and Rac3 was detectable in trigone tissues (n¼5 patients), bladder dome (n¼4 patients), and bladder wall (n¼2 patients). Western blot analysis for Rac1 revealed bands with expected sizes (ca. 21 kDa), and suggested protein expression in trigone, bladder dome, bladder wall, and mucosa, while Rac2 may lack in the mucosa, and Rac3 may lack in the detrusor. Active Rac1 was detectable in trigone and detrusor tissues by pull down of guanosine triphosphate-loaded Rac1 (GTP-Rac). In the organ bath, the muscarinic agonist carbachol (100 nM-1 mM) induced concentration-dependent contractions of trigone tissues, which were reduced by the Rac inhibitor EHT1864 (30 mM). This inhibition was observed in all included samples (n¼5 patients), despite high variations in magnitude of trigone contractions. Reduced contractility after Rac inhibition was reflected by decreased Emax value after curve fitting (111 AE17 % of KCl in the control group; 76 AE16 % of KCl after EHT1864). EHT1864 did not change EC50 values for carbachol, pointing to non-competitive inhibition of carbachol contractions.
CONCLUSIONS: Rac GTPases are active in the human trigone and detrusor. Smooth muscle contraction in the human trigone can be inhibited by the Rac inhibitor EHT1864. Rac-mediated trigone contractions may be involved in bladder outlet obstruction, in parallel to prostate-dependent mechanisms. Rac function in the bladder, including detrusor and overactive bladder merits further consideration.
INTRODUCTION AND OBJECTIVES:
The exact etiology of LUTS in human is still poorly understood. Alpha1-blockers are widely used in the treatment of LUTS associated with BPH. Tamsulosin has been reported to possess a potential of increasing blood flow in bladder microcirculation. Using a characterized rat model of chronic pelvic ischemia, we have studied the ameliorating potential of tamsulosin on the changes in bladder function caused by chronic ischemia.
METHODS: Chronic pelvic ischemia (CPI) was induced by causing bilateral endothelial injury of both iliac arteries and feeding a 2% cholesterol diet. A total of 60 male Sprague Dawley rats (18 weeks old) were divided into three groups: Control, CPI, and CPI-tamsulosin. The Control group received a regular diet and the CPI-tamsulosin group received tamsulosin (10 mg/kg/day) for 8 weeks. Eight weeks after surgery, half of the rats in the Control, CPI and CPI-tamsulosin groups were examined by cystometry and sacrificed for organ bath study. The other half of the rats from each group was examined 16 weeks after surgery (the CPI-tamsulosin group were continued treatment in the latter half of 8 weeks).
RESULTS: The iliac arteries from the AI showed neo-intimal proliferation and vascular occlusion. This was not prevented by tamsulosin treatment. After 8 weeks, there was no difference between CPI and CPI-tamsulosin groups in micturition interval (MI), bladder capacity (Bcap), and voiding volume (VV). Those parameters in both groups were significantly less than in the Control group (P<0.05). After 16 weeks, those parameters were improved in CPI-tamsulosin group without changing other parameters.
CONCLUSIONS: Tamsulosin treatment improved voiding function in rats with established chronic pelvic ischemia. The translational impact of this finding would be worth further study for improving the bladder function.
INTRODUCTION AND OBJECTIVES: TRPA1, a member of the Transient Receptor Potential (TRP) ion channel superfamily, is expressed in sensory afferents innervating the bladder, and activation of this channel induces urinary frequency in mice and rats. To investigate the role of TRPA1 in bladder physiology, researchers have often used HC030031 as a selective TRPA1 antagonist. In organ bath studies, concentrations between 1 and 100 mM are typically used. Preliminary data from our lab indicated inhibition of detrusor contractility with HC03031 (100 mM) in TRPA1 knock out mice.Our aim is to evaluate if HC030031 (100 mM) inhibits detrusor contractility in a TRPA1independent manner.
METHODS: The effect of HC030031 on detrusor contractility was examined in an organ bath study in wild type (WT) and TRPA1 knock-out (KO) C57Bl/6 mice. Contractile forces to cold (10 C), KCl (120 mM), carbachol (10 mM) and electrical field stimulation (EFS: 50V, 20Hz, 0,5ms, 10s) were recorded before, and after addition of HC030031 (100 mM), and following wash out. Contractile responses are reported as percentage of the first stimulus with the respective agonist. Statistical analyses were performed using Mann-Whitney U test and Kruskal-Wallis test.
RESULTS: In WT animals, HC030031 (100 mM) partially inhibited all tested agonist-induced detrusor contractions. We observed a 46 AE 5 % reduction of the contractile response to KCl, a 45 AE 4 % reduction to carbachol and a 32 AE 6 % reduction to EFS. Importantly, similar blocking potency was observed in TRPA1 KO-animals, where HC030031 (100 mM) inhibited the contractile response to KCl by 59 AE 5 % and to carbachol by 61 AE 4 %.
CONCLUSIONS: HC030031 (100 mM) inhibits detrusor contractility independent of TRPA1. Further research is necessary to investigate the target of HC030031.
